Macular Degeneration Treatment

Have you been diagnosed with early to mid-stage dry age-related Macular Degeneration (AMD) ?

Concerned about maintaining your independence—whether it’s driving, working, or enjoying your retirement? Burman and Zuckerbrod is excited to introduce the first approved Light Delivery treatment, Photobiomodulation, for Dry AMD.

There are two main types: dry AMD and wet AMD.

Dry Macular Degeneration

Dry AMD is the most common form of macular degeneration, accounting for about 80–90% of cases.
It occurs when cells in the macula gradually break down over time. Small yellow deposits called drusen may develop under the retina, and the macula can become thinner.

Dry AMD usually progresses slowly over years. In early stages, vision may be only mildly affected. In more advanced stages, central vision can become more significantly impaired.

While there is no cure for dry AMD, certain vitamin supplements, healthy lifestyle choices, and regular monitoring can help slow progression in some patients. In certain patients, photobiomodulation (PBM) may be an option to help improve vision.

Wet Macular Degeneration

Wet AMD is less common but more serious. It develops when abnormal blood vessels grow underneath the macula. These vessels can leak fluid or blood, causing rapid changes to the retina.
Wet AMD can progress quickly. However, modern treatments have dramatically improved outcomes.
Treatment typically involves injections of medication into the eye to stop the abnormal blood vessel growth and reduce bleeding. When detected early and treated promptly, many patients maintain useful vision.

Not smoking, maintaining a healthy diet rich in leafy greens, managing blood pressure, and protecting your eyes from UV light may help reduce your risk.

Personalized Care for Macular Degeneration
Although AMD cannot be reversed, early diagnosis and modern treatments allow many patients to preserve functional vision for years. Our goal is to detect changes early, slow progression, and provide timely treatment when needed.

If you have concerns about your central vision or a family history of macular degeneration, we encourage you to schedule an evaluation.
Valeda Light Therapy for Dry Macular Degeneration
Burman & Zuckerbrod Ophthalmology Associates, P.C. is proud to offer the Valeda Light Delivery System, a non-invasive treatment designed to help preserve vision in certain patients with dry age-related macular degeneration (AMD)

What Is Valeda Light Delivery System?

Valeda Light Delivery System uses a technology called photobiomodulation (PBM). This treatment delivers specific wavelengths of light to the retina and is thought to stimulate cellular energy production and improve retinal function.

The goal of treatment is to support the health of retinal cells, potentially improving vision in certain patients

Valeda is FDA-authorized for use in certain patients with dry AMD.

How Does Valeda Work?
In dry AMD, retinal cells can become stressed and less efficient at producing the energy they need to function properly. PBM therapy is thought to work by:

• Stimulating mitochondrial activity (the “energy centers” of cells)
• Improving cellular metabolism
• Supporting overall retinal health

Treatment is performed in the office and is:

• Non-invasive
• Painless
• No injections
• No surgery
• No downtime

Patients sit comfortably at the device while light is delivered to the eyes over a series of brief treatment sessions.

Treatment is typically delivered through a series of sessions over several weeks, repeated several times each year. Your doctor will recommend a customized treatment schedule based upon your unique needs.

Who May Benefit from Valeda?
Valeda is designed for patients with early to intermediate dry AMD.

In the past, treatments for dry macular degeneration were limited. Valeda offers advancements in treatment for select patients.

If you have been diagnosed with dry AMD and would like to learn whether Valeda may be appropriate for you, we invite you to call us today.

Syfovre for Advanced Dry Age-Related Macular Degeneration

Burman & Zuckerbrod Ophthalmology Associates, P.C. offers Syfovre, an innovative treatment option for patients with geographic atrophy, an advanced form of age-related macular degeneration (AMD). Syfovre is designed to help slow the progression and preserve vision for as long as possible.

Wondering if Syfovre might be an option for you?
Syfovre may be an option if:

• You have been diagnosed with geographic atrophy, an advanced form of age-related macular degeneration.
• Are looking for an FDA-approved treatment specifically targeting geographic atrophy progression
• Are comfortable with ongoing, in-office injection treatments as part of your routine care

Why consider treatment?
Geographic atrophy can progressively impact independence and quality of life. Early intervention with Syfovre may maintain functional vision longer.
Our doctors will carefully evaluate your condition and discuss whether Syfovre is appropriate for you, including potential benefits, risks, and treatment schedule.

Contact us today to schedule your appointment with one of our board-certified surgeons to see if you are a candidate for the Valeda Light Delivery System.